News | Proton Therapy | September 17, 2019

Key opinion leaders in the field of proton therapy shared their latest insights and research on Flash irradiation during IBA’s 3rd Victoria Consortium Meeting and IBA’s symposium on proton therapy

IBA Gathers Experts on Flash Irradiation During ASTRO

September 17, 2019 — IBA (Ion Beam Applications SA, held its third Victoria Consortium Meeting focusing on Flash irradiation at the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago.

In addition, during IBA’s annual symposium on proton therapy, Amit Maity, M.D., executive vice-chair radiation oncology, Perelman School of Medicine, University of Pennsylvania, also shared the latest insight on proton Flash radiation therapy for gastrointestinal (GI) malignancies.  

Flash therapy has the potential to dramatically change the landscape of radiotherapy and patient cancer care, making it more effective and more accessible than conventional radiotherapy. Flash irradiation is a fast and powerful treatment that delivers a high dose of radiation at an ultra-high dose rate. This novel technique could potentially shorten treatment time from 6-8 weeks to less than a week, and has the potential to reduce side effects for patients.

IBA is collaborating with several leading proton therapy centers in their research work to better understand the mechanisms of Flash irradiation. This early development work enables IBA today to deliver Flash irradiation on both its current single- and multi-room proton therapy platforms in a clinical environment in research mode, as demonstrated in March 2019 at the University Medical Center of Groningen, The Netherlands, and in June 2019 at the Rutherford Cancer Center Thames Valley in Reading, England. 

Alexander Lin, M.D., associate professor of radiation oncology and chief of the Head and Neck Oncology Service at the Hospital of the University of Pennsylvania, Philadelphia, commented, “Flash is a very exciting opportunity and we believe that proton therapy can be a very suitable modality to achieve the desired outcomes. We are at a stage where more research is needed to better understand the mechanisms of FLASH irradiation, and we are very excited about our current research program at Penn Medicine. Coordinating our efforts with other centers is key, and IBA’s Victoria meeting offered a great forum to share our insights.”

Flash therapy is currently under research and is not available for sale.

For more information: www.iba-worldwide.com


Related Content

News | ASTRO

Sept. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has named Siemens Healthineers the inaugural ...

Time September 29, 2026
arrow
News | Proton Therapy

Sept. 28, 2026 — Penn Medicine and Ion Beam Applications (IBA) have formed Noventra Oncology Alliance, a new joint ...

Time September 28, 2026
arrow
News | ASTRO

Sept. 22, 2026 — Leading experts in radiation therapy from the Abramson Cancer Center (ACC) of the University of ...

Time September 24, 2026
arrow
News | Molecular Imaging

Sept. 22, 2026 — Blue Earth Diagnostics, a part of the Bracco Group, has announced new research examining how precision ...

Time September 23, 2026
arrow
News | ASTRO

Sept.16, 2026 — For appropriately selected patients with muscle-invasive bladder cancer, preserving the bladder can be a ...

Time September 17, 2026
arrow
News | Radiology Imaging

Sept. 1, 2026 — Leo Cancer Care and GE HealthCare have announced that the two companies intend to work together on GE ...

Time September 11, 2026
arrow
News | ASTRO

Sept. 9, 2026 — The 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, will take place Sept. 26 to 30 ...

Time September 11, 2026
arrow
News | Radiation Oncology

Sept. 2, 2026 — Children with one of the deadliest forms of brain cancer may benefit from an additional course of ...

Time September 03, 2026
arrow
News | Radiation Therapy

Aug. 13, 2026 — An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence ...

Time August 17, 2026
arrow
News | Prostate Cancer

Aug. 13, 2026 — Artera has announced the enrollment of the first patient in its DIRECT-AI registry study, marking the ...

Time August 14, 2026
arrow
Subscribe Now